|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12...345678910111213...3738» |
- furosemide / Generic mfg.
Phase classification: MRS: The Effect of Plasma Osmolality on Brain Glutamate (clinicaltrials.gov) - Feb 9, 2016
P1, N=30, Completed, Sponsor: Yale University
Phase classification: P1/2 --> P1
- Trial primary completion date: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Feb 9, 2016
P2, N=40, Recruiting, Sponsor: Indiana University
Phase classification: P1/2 --> P1 Trial primary completion date: Dec 2015 --> Dec 2016
- |||| Trial completion, Trial primary completion date: e-CAeSAR: Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (clinicaltrials.gov) - Feb 9, 2016
P2, N=150, Completed, Sponsor: Posit Science Corporation
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015
- |||| Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Trial completion: Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole (clinicaltrials.gov) - Feb 4, 2016
P2, N=67, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- ||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment closed: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress (clinicaltrials.gov) - Feb 2, 2016
P3, N=837, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: TTIM: Improving Outcomes for Individuals With Serious Mental Illness and Diabetes (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=208, Completed, Sponsor: Case Western Reserve University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=22, Completed, Sponsor: Hôpital le Vinatier
Active, not recruiting --> Completed Recruiting --> Completed | N=40 --> 22 | Trial primary completion date: Dec 2011 --> Jul 2015
- |||| F17464 / Pierre Fabre
Trial completion, Enrollment change: F17464 in Acute Schizophrenia Trial (clinicaltrials.gov) - Jan 27, 2016
P2, N=171, Completed, Sponsor: Pierre Fabre Medicament
Recruiting --> Completed | N=40 --> 22 | Trial primary completion date: Dec 2011 --> Jul 2015 Active, not recruiting --> Completed | N=142 --> 171
- Trial completion, Enrollment change, Trial primary completion date: e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=177, Completed, Sponsor: Basque Health Service
Active, not recruiting --> Completed | N=142 --> 171 Recruiting --> Completed | N=260 --> 177 | Trial primary completion date: Jul 2013 --> Jun 2015
- Trial completion, Enrollment change: Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia (clinicaltrials.gov) - Jan 26, 2016
P1, N=11, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed | N=260 --> 177 | Trial primary completion date: Jul 2013 --> Jun 2015 Recruiting --> Completed | N=20 --> 11
- Trial completion: Remediation of Working Memory in Schizophrenia (clinicaltrials.gov) - Jan 23, 2016
P=N/A, N=80, Completed, Sponsor: VA Office of Research and Development
Recruiting --> Completed | N=20 --> 11 Active, not recruiting --> Completed
- || Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Jan 22, 2016
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2016
- Trial completion, Enrollment change, Trial primary completion date: Aftercare in the Community Health Center (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=41, Completed, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Completed | N=140 --> 41 | Trial primary completion date: Dec 2015 --> Apr 2015
- Trial primary completion date: STExFx: Short-term Working Memory and Executive Training (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=40, Recruiting, Sponsor: Queen's University
Recruiting --> Completed | N=140 --> 41 | Trial primary completion date: Dec 2015 --> Apr 2015 Trial primary completion date: Dec 2015 --> Jun 2016
- || Nuplazid (pimavanserin) / Acadia Pharma
Trial primary completion date: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Jan 21, 2016
P2, N=212, Recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Nov 2015 --> Jun 2016
- Trial primary completion date: The Austrian LEAD (Lung hEart sociAl boDy) Study (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=10000, Enrolling by invitation, Sponsor: LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Trial primary completion date: Nov 2015 --> Jun 2016 Trial primary completion date: Oct 2015 --> May 2016
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Enrollment change: Brexpiprazole in Patients With Schizophrenia (clinicaltrials.gov) - Jan 20, 2016
P3, N=210, Completed, Sponsor: H. Lundbeck A/S
Trial primary completion date: Oct 2015 --> May 2016 Active, not recruiting --> Completed | N=140 --> 210
- || osoresnontrine (BI 409306) / Boehringer Ingelheim
Trial primary completion date: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. (clinicaltrials.gov) - Jan 18, 2016
P2, N=516, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | N=140 --> 210 Trial primary completion date: Dec 2015 --> May 2016
- || pregabalin / Generic mfg.
Trial primary completion date: PACS: Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (clinicaltrials.gov) - Jan 18, 2016
P4, N=70, Recruiting, Sponsor: University of Aarhus
Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Feb 2016 --> Dec 2016
- Trial primary completion date, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=80, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Feb 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- Enrollment change: Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial (clinicaltrials.gov) - Jan 16, 2016
P=N/A, N=34, Recruiting, Sponsor: King's College London
Trial primary completion date: Dec 2015 --> Apr 2016 N=46 --> 34
- Trial completion, Enrollment change: Treatment Development Targeting Severe and Persistent Negative Symptoms (clinicaltrials.gov) - Jan 16, 2016
P=N/A, N=96, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=46 --> 34 Active, not recruiting --> Completed | N=50 --> 96
- Trial completion, Enrollment change: Social Cognitive Training for Psychosis: Treatment Development (clinicaltrials.gov) - Jan 15, 2016
P1, N=77, Completed, Sponsor: Yale University
Active, not recruiting --> Completed | N=50 --> 96 Active, not recruiting --> Completed | N=58 --> 77
- Disalcid (salsalate) / Bausch Health
Trial completion, Enrollment change, Trial primary completion date: Salsalate as an Adjunctive Treatment for Patients With Schizophrenia (clinicaltrials.gov) - Jan 15, 2016
P4, N=8, Completed, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | N=58 --> 77 Active, not recruiting --> Completed | N=17 --> 8 | Trial primary completion date: Dec 2015 --> Jul 2015
- Trial completion: Implementation of Illness Management and Recovery in Mental Health Services (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=40, Completed, Sponsor: University Hospital, Akershus
Active, not recruiting --> Completed | N=17 --> 8 | Trial primary completion date: Dec 2015 --> Jul 2015 Active, not recruiting --> Completed
- Enrollment open: Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients (clinicaltrials.gov) - Jan 15, 2016
P4, N=40, Recruiting, Sponsor: Beersheva Mental Health Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial completion: Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (clinicaltrials.gov) - Jan 12, 2016
P4, N=198, Completed, Sponsor: North Shore Long Island Jewish Health System
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- quetiapine / Generic mfg.
Trial completion, Enrollment change: The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain (clinicaltrials.gov) - Jan 12, 2016
P=N/A, N=20, Completed, Sponsor: Creighton University
Active, not recruiting --> Completed Recruiting --> Completed | N=40 --> 20
- ||||||| lurasidone / Generic mfg.
Trial completion: Pediatric Schizophrenia Efficacy and Safety Study (clinicaltrials.gov) - Jan 12, 2016
P3, N=285, Completed, Sponsor: Sunovion
Recruiting --> Completed | N=40 --> 20 Active, not recruiting --> Completed
- Trial initiation date, Trial primary completion date: Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study (clinicaltrials.gov) - Jan 6, 2016
P=N/A, N=70, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Initiation date: Sep 2013 --> Dec 2013 | Trial primary completion date: Sep 2016 --> Dec 2018
- Trial completion, Enrollment change: Shared Decision Making for Patients With First-admission Schizophrenia (clinicaltrials.gov) - Dec 30, 2015
P2/3, N=23, Completed, Sponsor: Yokohama City University
Initiation date: Sep 2013 --> Dec 2013 | Trial primary completion date: Sep 2016 --> Dec 2018 Active, not recruiting --> Completed | N=52 --> 23
- APN1125 / CoMentis, Alpharmagen
Enrollment closed, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects (clinicaltrials.gov) - Dec 25, 2015
P1, N=50, Active, not recruiting, Sponsor: CoMentis
Active, not recruiting --> Completed | N=52 --> 23 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jan 2016
- Trial completion, Enrollment change: SGE-PsyScan: Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan. (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=336, Completed, Sponsor: Maastricht University Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jan 2016 Active, not recruiting --> Completed | N=648 --> 336
- Trial completion, Trial primary completion date: Efficacy of Pregnenolone in Patients With Schizophrenia (clinicaltrials.gov) - Dec 22, 2015
P2, N=100, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | N=648 --> 336 Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Dec 2014
- Trial completion, Enrollment change, Trial initiation date: Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia (clinicaltrials.gov) - Dec 19, 2015
P2, N=400, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Dec 2014 Active, not recruiting --> Completed | N=180 --> 400 | Initiation date: Apr 2004 --> Mar 2015
- tolcapone / Generic mfg.
Trial completion: Clinical Trial of Tolcapone for Cognition in Schizophrenia (clinicaltrials.gov) - Dec 18, 2015
P2, N=212, Completed, Sponsor: National Institute of Mental Health (NIMH)
Active, not recruiting --> Completed | N=180 --> 400 | Initiation date: Apr 2004 --> Mar 2015 Recruiting --> Completed
- amisulpride / Generic mfg.
Trial primary completion date: Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=180, Recruiting, Sponsor: Birte Glenthoj
Recruiting --> Completed Trial primary completion date: Jan 2016 --> Jun 2016
- Trial completion, Enrollment change, Trial primary completion date: Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=47, Completed, Sponsor: Hôpital le Vinatier
Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Completed | N=100 --> 47 | Trial primary completion date: Sep 2014 --> Oct 2015
- || quetiapine extended-release / Generic mfg.
Enrollment change: Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=2292, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | N=100 --> 47 | Trial primary completion date: Sep 2014 --> Oct 2015 N=1400 --> 2292
- olanzapine / Generic mfg., sertraline / Generic mfg.
Trial primary completion date: STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) - Dec 15, 2015
P4, N=392, Recruiting, Sponsor: Weill Medical College of Cornell University
N=1400 --> 2292 Trial primary completion date: Jan 2016 --> Mar 2017
- Enrollment closed, Trial primary completion date: Assertive Community Treatment With CBT and SST for Schizophrenia (clinicaltrials.gov) - Dec 14, 2015
P=N/A, N=176, Active, not recruiting, Sponsor: Veterans Medical Research Foundation
Trial primary completion date: Jan 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016
- Enrollment closed, Enrollment change: Adaptive Treatment for Adolescent Cannabis Use Disorders (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=172, Active, not recruiting, Sponsor: University of Connecticut Health Center
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=230 --> 172
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change, Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Dec 12, 2015
P2, N=57, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=230 --> 172 Trial primary completion date: Dec 2014 --> Sep 2016 | N=37 --> 57
- amisulpride / Generic mfg., clozapine / Generic mfg.
Enrollment change, Trial withdrawal: Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=0, Withdrawn, Sponsor: Geha Mental Health Center
Trial primary completion date: Dec 2014 --> Sep 2016 | N=37 --> 57 N=140 --> 0 | Recruiting --> Withdrawn
- |||| lurasidone / Generic mfg.
Trial completion: High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (clinicaltrials.gov) - Dec 10, 2015
P4, N=101, Completed, Sponsor: Northwestern University
N=140 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed
- clozapine / Generic mfg.
Trial initiation date, Trial primary completion date: Vitamin D for Schizophrenia (clinicaltrials.gov) - Dec 10, 2015
P=N/A, N=50, Recruiting, Sponsor: Geha Mental Health Center
Recruiting --> Completed Initiation date: Jan 2013 --> May 2014 | Trial primary completion date: Jan 2014 --> Jun 2016
- metformin / Generic mfg., clozapine / Generic mfg.
Trial primary completion date: The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine (clinicaltrials.gov) - Dec 9, 2015
P4, N=30, Recruiting, Sponsor: Seoul National University Hospital
Initiation date: Jan 2013 --> May 2014 | Trial primary completion date: Jan 2014 --> Jun 2016 Trial primary completion date: Feb 2015 --> Apr 2016
- || paliperidone extended release / Generic mfg.
Trial primary completion date: Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients (clinicaltrials.gov) - Dec 9, 2015
P4, N=70, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Feb 2015 --> Apr 2016 Trial primary completion date: Mar 2014 --> Jul 2016
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion, Trial primary completion date: The Effect of Paliperidone Palmitate in Schizophrenia (clinicaltrials.gov) - Dec 9, 2015
P4, N=30, Completed, Sponsor: Seoul National University Hospital
Trial primary completion date: Mar 2014 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Dec 2015
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Risperdal Consta (risperidone depot formulation) / J&J
Trial completion, Trial primary completion date: Switching From Consta® to Sustenna® in Patients With Schizophrenia (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=50, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Mar 2014 --> May 2015